HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women
Autor: | Velja Mijatovic, Tatjana E. Vogelvang, M. J. Van Der Mooren, J. Willemse, Judith Leurs |
---|---|
Rok vydání: | 2005 |
Předmět: |
medicine.medical_specialty
Procarboxypeptidase U business.industry medicine.medical_treatment Placebo-controlled study Hematology Odds ratio law.invention Clinical trial Endocrinology Randomized controlled trial Selective estrogen receptor modulator law Internal medicine Fibrinolysis medicine Receptor business |
Zdroj: | Journal of thrombosis and haemostasis |
ISSN: | 1538-7836 1538-7933 |
DOI: | 10.1111/j.1538-7836.2005.01306.x |
Databáze: | OpenAIRE |
Externí odkaz: |